Literature DB >> 9524062

Cathepsin B and human tumor progression.

S Yan1, M Sameni, B F Sloane.   

Abstract

Cathepsin B has been implicated in progression of various human tumors. Overexpression of cathepsin B mRNA, increased cathepsin B staining and elevated cathepsin B activity have been found in different human cancers. These occur especially at the invasive edges of cancers, suggesting a role for cathepsin B in tumor invasion. In some tumors, mRNA expression and protein staining for cathepsin B correlate with clinical progression. Cathepsin B can facilitate tumor progression directly through degradation of components of the basement membrane and extracellular matrix. In vitro studies show that cathepsin B may exert its degradative effects intracellularly or extracellularly, depending on the cell type and location of cathepsin B. Cathepsin B can also facilitate tumor progression indirectly through activation of other latent proteases and/or degradation of protein inhibitors of other proteases. Thus cathepsin B may be an integral component of the proteolytic cascade linked to malignant progression of human tumors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9524062

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  26 in total

1.  Cyclic, linear, cycloretro-isomer, and cycloretro-inverso peptides derived from the C-terminal sequence of bradykinin as substrates or inhibitors of serine and cysteine proteases.

Authors:  Aurelio Resende Lima; Luiz Juliano; Maria Aparecida Juliano
Journal:  Protein J       Date:  2004-05       Impact factor: 2.371

2.  Effects of symptomatic and asymptomatic isolates of Blastocystis hominis on colorectal cancer cell line, HCT116.

Authors:  Kok Hoe Chan; Samudi Chandramathi; Kumar Suresh; Kek Heng Chua; Umah Rani Kuppusamy
Journal:  Parasitol Res       Date:  2012-01-26       Impact factor: 2.289

Review 3.  Cystatin superfamily.

Authors:  Josiah Ochieng; Gautam Chaudhuri
Journal:  J Health Care Poor Underserved       Date:  2010-02

4.  Selective in vivo metabolic cell-labeling-mediated cancer targeting.

Authors:  Hua Wang; Ruibo Wang; Kaimin Cai; Hua He; Yang Liu; Jonathan Yen; Zhiyu Wang; Ming Xu; Yiwen Sun; Xin Zhou; Qian Yin; Li Tang; Iwona T Dobrucki; Lawrence W Dobrucki; Eric J Chaney; Stephen A Boppart; Timothy M Fan; Stéphane Lezmi; Xuesi Chen; Lichen Yin; Jianjun Cheng
Journal:  Nat Chem Biol       Date:  2017-02-13       Impact factor: 15.040

5.  Enhanced tumor retention of NTSR1-targeted agents by employing a hydrophilic cysteine cathepsin inhibitor.

Authors:  Wei Fan; Wenting Zhang; Sameer Alshehri; Trey R Neeley; Jered C Garrison
Journal:  Eur J Med Chem       Date:  2019-05-25       Impact factor: 6.514

6.  Cathepsin L increased level upon Ras mutants expression: the role of p38 and p44/42 MAPK signaling pathways.

Authors:  Lorena Urbanelli; Francesco Trivelli; Luisa Ercolani; Eleonora Sementino; Alessandro Magini; Brunella Tancini; Raffaella Franceschini; Carla Emiliani
Journal:  Mol Cell Biochem       Date:  2010-06-04       Impact factor: 3.396

Review 7.  Proteolytic-antiproteolytic balance and its regulation in carcinogenesis.

Authors:  Elzbieta Skrzydlewska; Mariola Sulkowska; Mariusz Koda; Stanislaw Sulkowski
Journal:  World J Gastroenterol       Date:  2005-03-07       Impact factor: 5.742

8.  Cathepsin B carboxydipeptidase specificity analysis using internally quenched fluorescent peptides.

Authors:  Maria Helena S Cezari; Luciano Puzer; Maria Aparecida Juliano; Adriana K Carmona; Luiz Juliano
Journal:  Biochem J       Date:  2002-11-15       Impact factor: 3.857

9.  Characterization of gene expression induced by RET with MEN2A or MEN2B mutation.

Authors:  Tsuyoshi Watanabe; Masatoshi Ichihara; Mizuo Hashimoto; Keiko Shimono; Yoshie Shimoyama; Tetsuro Nagasaka; Yoshiki Murakumo; Hideki Murakami; Hideshi Sugiura; Hisashi Iwata; Naoki Ishiguro; Masahide Takahashi
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

10.  Cystatin E/M suppresses legumain activity and invasion of human melanoma.

Authors:  Jon J Briggs; Mads H Haugen; Harald T Johansen; Adam I Riker; Magnus Abrahamson; Øystein Fodstad; Gunhild M Maelandsmo; Rigmor Solberg
Journal:  BMC Cancer       Date:  2010-01-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.